Hopewell Therapeutics
Woburn, MA · Biotechnology · 25 employees
Hopewell Therapeutics is discovering, synthesizing and developing the next generation of tissue-targeted lipid nanoparticles (ttLNPs) to bring genomic medicines to patients. We are pursuing opportunities to redefine the non-viral delivery space for novel genomic medicines by designing systemically administered LNPs to specifically target extrahepatic tissues and cells throughout the body. Hopewell
Funding history
- Seed — $2.5M — Sep 2025
- Venture - Series Unknown — $7.8M — May 2024
- Seed — $25.0M — Jun 2023
- Seed — $3.0M — Jun 2023
- Venture - Series Unknown — $7.1M — Feb 2022
Recent signals
- Sep 17, 2025: Raised $2.5M in Seed
- May 17, 2024: Raised $7.8M in Venture - Series Unknown
- Jun 07, 2023: Raised $25.0M in Seed
- Jun 02, 2023: Raised $3.0M in Seed
- Feb 02, 2022: Raised $7.1M in Venture - Series Unknown
- Oct 08, 2021: Raised $8.0M in Venture - Series Unknown
- Dec 21, 2020: Raised $7.8M in Venture - Series Unknown
See plans & pricing → Track Hopewell Therapeutics’s funding, hiring, and signals — with verified contacts — on Fundz.